MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress [Yahoo! Finance]
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: Yahoo! Finance
company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET. “Throughout 2024, MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe immune-related disorders,” said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics. “We made significant clinical strides, strengthened our manufacturing foundation, and forged strategic alliances. Through disciplined capital management, we are positioned
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business ProgressGlobeNewswire
- MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial ReportGlobeNewswire
- MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target raised by analysts at HC Wainwright from $9.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting [Yahoo! Finance]Yahoo! Finance
INKT
Earnings
- 3/18/25 - Miss
INKT
Analyst Actions
- 3/18/25 - HC Wainwright
INKT
Sec Filings
- 3/18/25 - Form 10-K
- 3/18/25 - Form 8-K
- 3/5/25 - Form 4
- INKT's page on the SEC website